anti-kras g12v mtcr
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 4, 2017 (NCT03190941)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- GTPase KRasImmunity, passive
KRAS immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- anti-kras g12v mtcr
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04146298 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2019 | Changhai Hospital, Providence Health & Services |
| NCT03190941 | Phase 1/Phase 2 (Phase 2) | Jul 4, 2017 | National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Changhai Hospital | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2017 |
| Providence Health & Services | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1